Targeting SMOX Preserves Optic Nerve Myelin, Axonal Integrity, and Visual Function in Multiple Sclerosis

Area of Science:

• Neuroscience
• Immunology
• Pharmacology

Background:

• Multiple sclerosis (MS) is a disabling neurological disease characterized by inflammation, demyelination, and axonal damage.
• Previous research indicated that inhibiting spermine oxidase (SMOX) with MDL72527 reduced symptoms and damage in an MS model (EAE).

Purpose of the Study:

• To investigate the therapeutic potential of SMOX inhibition for myelin preservation, axonal integrity, and visual function in the EAE model.
• To explore the role of galectin-3 (Gal3) in SMOX-mediated neuroprotection.

Main Methods:

• Electron microscopy and immunofluorescence were used to assess myelin and axonal integrity in the optic nerve of EAE mice treated with MDL72527.
• Quantitative analysis of g-ratio and axon count metrics.
• Electroretinography (ERG) was performed to evaluate retinal ganglion cell (RGC) function and axonal conduction.
• Western blotting or similar techniques were used to assess Gal3 expression.

Main Results:

• SMOX inhibition with MDL72527 significantly preserved myelin thickness and axonal integrity in the optic nerve.
• Quantitative metrics (g-ratio, axon count) showed significant improvement in MDL72527-treated EAE mice.
• Functional assessments via ERG demonstrated improved RGC function and axonal conduction.
• SMOX inhibition led to downregulation of galectin-3 (Gal3) expression.

Conclusions:

• SMOX inhibition effectively preserves myelin and axons, improving visual function in the EAE model.
• The findings support SMOX inhibition as a potential therapeutic strategy for multiple sclerosis and other demyelinating disorders.
• Galectin-3 may play a role in the neuroprotective effects of SMOX inhibition.